A Practical Concept for Preoperative Identification of Patients with Impaired Primary Hemostasis

Abstract

The findings of a large prospective study designed to identify primary and/or secondary hemostatic disorders before surgical interventions are presented. A total of 5649 unselected adult patients were enrolled to identify impaired hemostasis before surgical interventions. Each patient was asked to answer a standardized questionnaire concerning bleeding history. Activated partial thromboplastin time (aPTT), prothrombin time (PT), and platelet counts (PC) including PFA-100 (platelet function analyzer): collagen-epinephrine (C/E), and collagen-ADP (C/ADP) were routinely done in all patients. Additional tests, bleeding time (BT), and von Willebrand factor (vWF: Ag) were performed only in patients with a positive bleeding history and/or evidence of impaired hemostasis; e.g., drug ingestion. The bleeding history was negative in 5021 patients (88.8%) but positive in the remaining 628 (11.2%). Impaired hemostasis could be verified only in 256 (40.8%) of these patients. The vast majority were identified with PFA-100: C/E (n=250; 97.7%). The other six patients with impaired hemostasis were identifiable solely based on the PT (n=2), PFA-100: C/ADP (n=2), and vWF: Ag (n=2). The PFA-100: C/ADP detected 199 patients (77.7%). The only abnormality found among patients with a negative bleeding history was a prolonged aPTT due to lupus anticoagulant in nine patients (0.2%). The sensitivity of the PFA-100: collagen-epinephrine was the highest (90.8%) in comparison to the other screening tests (BT, aPTT, PT, vWF: Ag). The positive predictive value of the PFA-100: collagen-epinephrine was high (81.8%), but the negative predictive value was higher (93.4%). The use of a standardized questionnaire and, if indicated, the PFA-100: C/E and/or other specific tests not only ensure the detection of impaired hemostasis in almost every case but also a significant reduction of the cost.

Keywords

Standardized questionnaire of bleeding history Hemostatic screening tests PFA-100 Bleeding time Coagulation tests

References

Bowie EJW . Recognition of easily missed bleeding diseases. Mayo Clin Proc 1982;57:263.

Rapaport S.

Preoperative hemostatic evaluation: Which tests, if any?

Blood 1983;61:229.

Borzotta AP , Keeling MM . Value of the preoperative history as an indicator of hemostatic disorders. Ann Surg 1984;200:648.

Srámek A , Eikenboom J , Briet E , Vandenbroucke J , Rosendaal F. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995;155:1409.

Eika C , Havig O , Godal HC . The value of preoperative hemostatic screening. Scand J Haematol 1978;21:349.

Kaplan E , Sheiner L , Boeckmann A , Roizen M , Beal S , Cohen S , Nicoll D. The usefulness of preoperative laboratory screening. JAMA 1985;253:3576.

Barber A , Green D , Galluzzo T , Tsào C-H. The bleeding time as a preoperative screening test. Am J Med 1985;78:761.

Rohrer MJ , Michelotti MC , Nahrwold DL . A prospective evaluation of the efficacy of preoperative coagulation testing. Ann Surg 1988;208:554.

Rodgers RP , Levin J. A critical reappraisal of the bleeding time. Sem Throm Haemost 1990;16:1.

10.

Lind SE . The bleeding time does not predict surgical bleeding. Blood 1991;77:2547.

11.

Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: A multivariate analysis. Surgery 1991;109:236.

12.

Macpherson CR , Jacobs P , Dent DM . Abnormal perioperative hemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J 1993;83:106.

13.

Houry S , Georgeac C , Hay JM , Fingerhut A , Boudet JJ . A prospective multicenter evaluation of preoperative hemostatic screening tests. Am J Surg 1995;170:75.

14.

Miller CH , Lenzi R , Breen C. Prevalence of von Willebrand’s disease among U.S. adults. Blood 1987;70:377.

15.

George JN , Shattil SJ . The clinical importance of acquired abnormalities of platelet function. N Engl J Med 1991;324:27.

16.

Kundu SK , Sio R , Mitu A , Ostgaard RA . Evaluation of platelet function by PFA-100. Clin Chem 1994;40:1827.

17.

Despotis GJ , Levine V , Filos KS . Evaluation of a new, point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 1996;85:1311.

18.

Mammen E , Comp P , Gosselin R , Greenberg C , Hoots W , Kessler C , Larkin E , Liles D , Nugent D. PFA-100TM System: A new method for assessment of platelet dysfunction. Sem Thromb Haemost 1998;24:195.

19.

Cattaneo M , Federici AB , Lecchi A , Agati B , Lombardi R , Stabile F , Bucciarelli P. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82(1):35.

20.

Harrison P , Robinson MS , Mackie IJ , Joseph J , McDonald SJ , Liesner R , Savidge GF , Pasi J , Machin SJ . Performance of the platelet function analyser PFA-100 in testing abnormalities of primary hemostasis. Blood Coag Fibrinolysis 1999;10:25.

21.

Cattaneo M , Lecchi A , Agati B , Lombardi R , Zighetti ML . Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999;96:213.

22.

Böck M , De Haan J , Beck KH , Gutensohn K , Hertfelder HJ , Karger R , Heim MU , Beeser H , Weber D , Kretschmer V. Standardization of the PFA-100 platelet function test in 105 mmol/l bufffered citrate: Effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898.

23.

Budde U , Schneppenheim R , Plendl H , Dent J , Ruggeri ZM , Zimmermann TS . Luminographic detection of von Willebrand factor multimers in agarose gels and on nitro-cellulose membranes. Thromb Haemost 1990;63:312.

24.

Sadler JE . A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520.

25.

Sachs L . Angewandte Statistik. Berlin: Springer Verlag, 1984:1.

26.

Büttner J. Die Beurteilung des diagnostischen Wertes klinisch-chemischer Untersuchungen. J Clin Chem Biochem 1977;15:1.

27.

Galen S , Gambino SR . Norm und Normabweichung klinischer Daten. Stuttgart: Gustav Fischer Verlag, 1979:4.

28.

Kundu SK , Heilmann EJ , Sio R , Garcia C , Davidson RS , Ostgaard RA . Description of an in vitro platelet function analyser—PFA-100. Semin Thromb Haemost 1995;21 (Suppl 2):106.

29.

Koscielny J , Blaicher AM , Felfernig D , Latza R , Wenzel E , Kiesewetter H. Consensus use of desmopressin and antifibrinolytics in three university clinics. Anaesthesia 1998;53:60.

30.

Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002;87(11):1122.

31.

Kenet G , Lubetsky A , Shenkman B , Tamarin I , Dardik R , Rechavi G , Barzilai A , Martinowitz U , Savion N , Varon D. Cone and platelet analyser (CPA): A new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998;101:255.

32.

Koscielny J , von Tempelhoff GF , Ziemer S , Radtke H , Schmutzler M , Sinha P , Salama A , Kiesewetter H , Latza R. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2003;10(2):155.